The Septic Shock drugs in development market research report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Septic Shock. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Septic Shock and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Septic Shock by 19 companies/universities/institutes. The top development phase for Septic Shock is preclinical with nine drugs in that stage. The Septic Shock pipeline has 18 drugs in development by companies and three by universities/ institutes. Some of the companies in the Septic Shock pipeline products market are: Salzman Group, Matisse Pharmaceuticals and Aptahem.
The key targets in the Septic Shock pipeline products market include N(G),N(G)-Dimethylarginine Dimethylaminohydrolase 1 (Dimethylarginine Dimethylaminohydrolase 1 or Dimethylargininase 1 or DDAH1 or EC 3.5.3.18), Myeloid Differentiation Primary Response Protein MyD88 (MYD88), and Lipopolysaccharide (Endotoxin).
See Also:
The key mechanisms of action in the Septic Shock pipeline product include Alpha 1 Adrenergic Receptor (ADRA1) Antagonist with one drug in Phase II. The Septic Shock pipeline products include five routes of administration with the top ROA being Intravenous and seven key molecule types in the Septic Shock pipeline products market including Small Molecule, and Synthetic Peptide.
Septic Shock overview
Septic shock, the most severe complication of sepsis, occurs in response to an inciting agent, which causes both pro-inflammatory and anti-inflammatory immune system activation. It involves very low blood pressure, an altered mental state, and organ dysfunction. Sepsis syndromes are often caused by multidrug-resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), among others.
For a complete picture of Septic Shock’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
